Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Agnuside SCHEMBL24174405 | 1.00 | L3MBTL1 (0.67) | L3MBTL1HSP90AA1XDHTYRCA12 | |
| Agnuside SCHEMBL382107 | 1.00 | L3MBTL1 (0.67) | L3MBTL1HSP90AA1XDHTYRCA12 | |
| SCHEMBL7153129 | 0.93 | L3MBTL1 (0.67) | L3MBTL1HSP90AA1XDHCA12CA1 | |
| Eurostoside SCHEMBL29425819 | 0.85 | L3MBTL1 (0.62) | L3MBTL1HSP90AA1XDHCA12CA1 | |
| SCHEMBL29425816 | 0.83 | L3MBTL1 (0.63) | L3MBTL1HSP90AA1XDHTYR | |
| Aucubin SCHEMBL381032 | 0.81 | L3MBTL1 (1.00) | L3MBTL1HSP90AA1XDH | |
| Aucubin SCHEMBL22680275 | 0.81 | L3MBTL1 (1.00) | L3MBTL1HSP90AA1XDH | |
| Aucubin SCHEMBL22680274 | 0.81 | L3MBTL1 (1.00) | L3MBTL1HSP90AA1XDH | |
| SCHEMBL13998199 | 0.78 | KMT2A (0.42) | L3MBTL1HSP90AA1CA12CA1CA2 | |
| SCHEMBL382085 | 0.77 | STAT3 (0.44) | L3MBTL1HSP90AA1TYRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364255-B2 | Therapeutic herbal compositions for improving joint health | KARALLIEF, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20220000898-A1 | THERAPEUTIC HERBAL COMPOSITIONS FOR IMPROVING JOINT HEALTH | Karallief Inc. | 2022-01-06 | — | — | US | disclosed |
| US-7780997-B2 | Pharmaceutically active extracts of vitex leucoxylon, a process of extracting the same and a method of treating diabetes and inflammatory diseases therewith | LAILA IMPEX (IN) | 2010-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000898-A1 | THERAPEUTIC HERBAL COMPOSITIONS FOR IMPROVING JOINT HEALTH | RDX, HAGH, BROX | L3MBTL1 3535/4885HSP90AA1 164/4885XDH 3485/4885 |
| US-11364255-B2 | Therapeutic herbal compositions for improving joint health | RDX, HAGH, BROX | L3MBTL1 3535/4885HSP90AA1 164/4885XDH 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.